Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editor's pick

17-05-2019 | Small-cell lung cancer | Highlight | News

CTCs prognostic in limited-stage SCLC

The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.

10-04-2019 | Urothelial cancer | Video | Article

Adjuvant chemotherapy for upper tract urothelial cancer

Dr Alison Birtle (Rosemere Cancer Centre, Royal Preston Hospital, UK) discusses the rationale for adjuvant chemotherapy for upper tract urothelial cancer (UTUC), the POUT trial and its practice-changing implications for treatment of UTUC.

23-03-2019 | Pancreatic cancer | Case study | Collection

New options in metastatic pancreatic cancer: Interactive patient cases

These two case studies are intended for global medical, surgical and radiation oncologists, gastroenterologists, and other healthcare providers involved in the management of patients with pancreatic cancer, and any other clinicians involved in the diagnosis, treatment and follow-up of patients with PDAC.

Developed with an independent educational grant from Shire and supported by Servier.

Get ready for ASCO 2019

View our abstract recommendations in advance of our coverage of the 2019 ASCO Annual Meeting in Chicago (May 31–June 4).

Specialty

Latest from across the site

23-05-2019 | Urothelial cancer | News

Sustained nivolumab, ipilimumab activity shown in advanced urothelial cancer

Extended follow-up of patients with unresectable locally advanced or metastatic urothelial carcinoma in the CheckMate 032 trial shows sustained antitumor activity of nivolumab alone and in combination with ipilimumab.

22-05-2019 | Clinical trial | News

Waterfall plot diagrams may overestimate response rate

Waterfall plots visually overestimate the tumor response rate to agents being tested in clinical trials, US researchers warn in JAMA Network Open.

21-05-2019 | Mesothelioma | News

No benefit with nintedanib in advanced malignant pleural mesothelioma

Adding nintedanib to pemetrexed plus cisplatin does not improve progression-free survival for patients with advanced malignant pleural mesothelioma, say researchers who conducted a phase III trial on the basis of earlier positive findings.

20-05-2019 | Prostate cancer | News

Poor glycemic control linked to prostate cancer progression

In men with prostate cancer and diabetes, higher glycated hemoglobin levels are associated with an increased risk for developing metastases and castration-resistant disease, findings indicate.

17-05-2019 | Small-cell lung cancer | Highlight | News

CTCs prognostic in limited-stage SCLC

The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.

17-05-2019 | FDA | News

USA approves first-line avelumab–axitinib for advanced RCC

Click through to read more

Meet the Editorial Board


Our international Editorial Board members Dr Fiona Blackhall (Christie Hospital, Manchester, UK) and Dr Axel Merseburger (University Hospital Schleswig-Holstein, Germany) work closely with the editorial team to highlight gaps in coverage and select topics to feature on this digital platform.

Why register? Medicine Matters oncology is a free resource providing the latest news and clinical guidance

Register today and receive updates directly to your inbox!
Medicine Matters oncology has been specifically developed for the time-limited healthcare professional who is looking for a single resource providing credible information on current practice and the latest advances in oncology.
Already registered? Log in now to unlock your access.

Latest from us on Twitter

Updates from oncology organizations

New Content Item Meet our Advisory Board

Image Credits